Cambridge Healthtech Institute’s Inaugural

Immuno-Oncology: Emerging Targets and Therapeutics

New Ways to Refocus the Immune System to Attack Cancer

September 17-18, 2019


The paradigm of immuno-oncology: figuring out and then circumventing how cancer cells evade the immune system, has been validated by a few high-impact therapeutic successes in the past few years and has thus spurred a flurry of more drug discovery and development in the field. However much of the current pharmaceutical activity is focused on a few cell surface drug targets and their inhibition by biologics-based therapies. CHI’s Inaugural Immuno-Oncology: Emerging Targets and Therapeutics conference will cover newer cell surface targets in the IO field that are being investigated for modulation by biologics as well as by other modalities, especially small molecules that have the potential to be oral-based medicines. We will also cover drug targets that are intracellular, thus only accessible to small molecules or newer, non-biologic modalities. Please join us to stay abreast of this rapidly progressing field.


Who should attend: Head of departments, Immunologists, Oncology Researchers, Discovery Biologists, Discovery Chemists, Protein Engineers, Biologics Discovery, Professors, Principal Scientists, Senior Scientists, CSOs, Director-level Scientists from departments such as: Cancer Drug Discovery, Immuno-oncology, Immunotherapeutics, Oncology.  


Coverage will include, but is not limited to:

  • Activating innate immunity through pattern recognition receptors (TLRs, RIG-1 like receptors, Nod-like receptors, C-type lectin receptor, DNA sensors (STING agonists)
  • Targeting tumor-associated macrophages (TAMs) such as receptor tyrosine kinases (RTKs) and lectin receptors
  • Targeting chemokine receptors (CXCR2, CXCR4)
  • Inhibiting checkpoint blockade targets other than PD1/CTLA4 (such as TIM3, LAG3, VISTA, TIGIT)
  • Small molecule inhibitors of checkpoint blockade (including PD1/CTLA4) targets
  • Immune-metabolism targets (cell surface and intracellular) that affect the tumor micro-environment (TME):

-         Arginase pathway

-         IDO-kyneurin-Aryl hydrocarbon Pathway

-         Adenosine pathway: CD73, CD39, A2AR

-         Methionine pathway: methionine adenosyltransferase 2a (MAT2A)


If you would like to submit a proposal to give a presentation at this meeting, please click here.


The deadline for priority consideration is February 27, 2019.


All proposals are subject to review by session chairmen and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.


For more details on the conference, please contact:
Anjani Shah, PhD

Senior Conference Director

Cambridge Healthtech Institute

Phone: (+1) 781-247-6252


For partnering and sponsorship information, please contact:
Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286

Premier Sponsors

Ablexis Alivamab_stacked



OmniAb Ligand_Pharmaceuticals